The human proton-coupled folate transporter

References

• Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC 2nd, Lenz GG. The Action of Pteroylglutamic Conjugates on Man. Science 1947; 106:619 - 21; http://dx.doi.org/10.1126/science.106.2764.619; PMID: 17831847
   PubMed Web of Science ®Google Scholar
• Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238:787 - 93; http://dx.doi.org/10.1056/NEJM194806032382301; PMID: 18860765
   PubMed Web of Science ®Google Scholar
• Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 1949; 4:160 - 7; PMID: 18107667
   PubMed Web of Science ®Google Scholar
• Monahan BP, Allegra CJ. Antifolates. In: Chabner BA, Longo, D.L., ed. Cancer Chemotherapy and Biotherapy. Philadelphia, PA: Lippincott Williams and Wilkins, 2011:109-38.
   Google Scholar
• Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431 - 57; http://dx.doi.org/10.1038/sj.onc.1206946; PMID: 14576850
   PubMed Web of Science ®Google Scholar
• Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004; 9:482 - 8; http://dx.doi.org/10.1634/theoncologist.9-5-482; PMID: 15477632
   PubMed Web of Science ®Google Scholar
• Cohen MH, Justice R, Pazdur R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 2009; 14:930 - 5; http://dx.doi.org/10.1634/theoncologist.2009-0092; PMID: 19737998
   PubMed Web of Science ®Google Scholar
• Thompson CA. FDA approves pralatrexate for treatment of rare lymphoma. Am J Health Syst Pharm 2009; 66:1890; http://dx.doi.org/10.2146/news090080; PMID: 19850775
   PubMed Web of Science ®Google Scholar
• Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005; 65:11721 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-2034; PMID: 16357184
   PubMed Web of Science ®Google Scholar
• Yang J, Vlashi E, Low P. Folate-linked drugs for the treatment of cancer and inflammatory diseases. Subcell Biochem 2012; 56:163 - 79; http://dx.doi.org/10.1007/978-94-007-2199-9_9; PMID: 22116699
   PubMedGoogle Scholar
• Wang L, Cherian C, Kugel Desmoulin S, Mitchell-Ryan S, Hou Z, Matherly LH, et al. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier. J Med Chem 2012; 55:1758 - 70; http://dx.doi.org/10.1021/jm201688n; PMID: 22243528
   PubMed Web of Science ®Google Scholar
• Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, et al. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 2011; 80:1096 - 107; http://dx.doi.org/10.1124/mol.111.073833; PMID: 21940787
   PubMed Web of Science ®Google Scholar
• Wang L, Desmoulin SK, Cherian C, Polin L, White K, Kushner J, et al. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase. J Med Chem 2011; 54:7150 - 64; http://dx.doi.org/10.1021/jm200739e; PMID: 21879757
   PubMed Web of Science ®Google Scholar
• Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, et al. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 2010; 78:577 - 87; http://dx.doi.org/10.1124/mol.110.065896; PMID: 20601456
   PubMed Web of Science ®Google Scholar
• Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, et al. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 2010; 53:1306 - 18; http://dx.doi.org/10.1021/jm9015729; PMID: 20085328
   PubMed Web of Science ®Google Scholar
• Deng Y, Zhou X, Kugel Desmoulin S, Wu J, Cherian C, Hou Z, et al. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. J Med Chem 2009; 52:2940 - 51; http://dx.doi.org/10.1021/jm8011323; PMID: 19371039
   PubMed Web of Science ®Google Scholar
• Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, et al. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem 2008; 51:5052 - 63; http://dx.doi.org/10.1021/jm8003366; PMID: 18680275
   PubMed Web of Science ®Google Scholar
• Stokstad ELR. Historical Perspective on Key Advances in the Biochemistry and Physiology of Folates. In: Picciano MF, Stokstad, E.L.R., Spector, R., ed. Folic Acid Metabolism in Health and Disease. New York: Wiley-Liss, 1990:1-21.
   Google Scholar
• Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 1989; 45:263 - 335; http://dx.doi.org/10.1016/S0083-6729(08)60397-0; PMID: 2688305
   PubMed Web of Science ®Google Scholar
• Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9:227 - 46; http://dx.doi.org/10.1016/j.drup.2006.09.001; PMID: 17092765
   PubMed Web of Science ®Google Scholar
• Lu SC. S-Adenosylmethionine. Int J Biochem Cell Biol 2000; 32:391 - 5; http://dx.doi.org/10.1016/S1357-2725(99)00139-9; PMID: 10762064
   PubMed Web of Science ®Google Scholar
• Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007; 26:111 - 28; http://dx.doi.org/10.1007/s10555-007-9046-2; PMID: 17334909
   PubMed Web of Science ®Google Scholar
• Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004; 56:1067 - 84; http://dx.doi.org/10.1016/j.addr.2004.01.001; PMID: 15094207
   PubMed Web of Science ®Google Scholar
• Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009; 11:e4; http://dx.doi.org/10.1017/S1462399409000969; PMID: 19173758
   PubMed Web of Science ®Google Scholar
• Zhao R, Goldman ID. The molecular identity and characterization of a Proton-coupled Folate Transporter--PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 2007; 26:129 - 39; http://dx.doi.org/10.1007/s10555-007-9047-1; PMID: 17340171
   PubMed Web of Science ®Google Scholar
• Visentin M, Chang MH, Romero MF, Zhao R, Goldman ID. Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol 2012; 81:134 - 42; http://dx.doi.org/10.1124/mol.111.074823; PMID: 22021325
   PubMed Web of Science ®Google Scholar
• Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1998; 1375:6 - 12; http://dx.doi.org/10.1016/S0005-2736(98)00118-7; PMID: 9767079
   PubMed Web of Science ®Google Scholar
• Hou Z, Matherly LH. Oligomeric structure of the human reduced folate carrier: identification of homo-oligomers and dominant-negative effects on carrier expression and function. J Biol Chem 2009; 284:3285 - 93; http://dx.doi.org/10.1074/jbc.M807206200; PMID: 19019821
   PubMed Web of Science ®Google Scholar
• Hou Z, Cherian C, Drews J, Wu J, Matherly LH. Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. J Biol Chem 2010; 285:4732 - 40; http://dx.doi.org/10.1074/jbc.M109.086033; PMID: 20018840
   PubMed Web of Science ®Google Scholar
• Zhao R, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011; 31:177 - 201; http://dx.doi.org/10.1146/annurev-nutr-072610-145133; PMID: 21568705
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002; 367:629 - 40; http://dx.doi.org/10.1042/BJ20020512; PMID: 12144527
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao R, Russell RG, Goldman ID. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta 2001; 1513:49 - 54; http://dx.doi.org/10.1016/S0005-2736(01)00340-6; PMID: 11427193
   PubMed Web of Science ®Google Scholar
• Zhao R, Russell RG, Wang Y, Liu L, Gao F, Kneitz B, et al. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 2001; 276:10224 - 8; PMID: 11266438
   PubMed Web of Science ®Google Scholar
• Liu M, Ge Y, Cabelof DC, Aboukameel A, Heydari AR, Mohammad R, et al. Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. J Biol Chem 2005; 280:5588 - 97; http://dx.doi.org/10.1074/jbc.M412662200; PMID: 15579899
   PubMed Web of Science ®Google Scholar
• Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ. Endocytosis of GPI-linked membrane folate receptor-alpha. J Cell Biol 1996; 132:35 - 47; http://dx.doi.org/10.1083/jcb.132.1.35; PMID: 8567728
   PubMed Web of Science ®Google Scholar
• Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004; 56:1099 - 109; http://dx.doi.org/10.1016/j.addr.2004.01.010; PMID: 15094209
   PubMed Web of Science ®Google Scholar
• Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RG. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988; 263:13602 - 9; PMID: 3417674
   PubMed Web of Science ®Google Scholar
• Zhao R, Min SH, Wang Y, Campanella E, Low PS, Goldman ID. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem 2009; 284:4267 - 74; http://dx.doi.org/10.1074/jbc.M807665200; PMID: 19074442
   PubMed Web of Science ®Google Scholar
• Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002; 100:594 - 602; http://dx.doi.org/10.1182/blood.V100.2.594; PMID: 12091353
   PubMed Web of Science ®Google Scholar
• Chancy CD, Kekuda R, Huang W, Prasad PD, Kuhnel JM, Sirotnak FM, et al. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 2000; 275:20676 - 84; http://dx.doi.org/10.1074/jbc.M002328200; PMID: 10787414
   PubMed Web of Science ®Google Scholar
• Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992; 52:6708 - 11; PMID: 1330299
   PubMed Web of Science ®Google Scholar
• Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood 1999; 93:3940 - 8; PMID: 10339503
   PubMed Web of Science ®Google Scholar
• Veggian R, Fasolato S, Ménard S, Minucci D, Pizzetti P, Regazzoni M, et al. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori 1989; 75:510 - 3; PMID: 2481353
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr., Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993; 142:557 - 67; PMID: 8434649
   PubMed Web of Science ®Google Scholar
• Buist MR, Molthoff CF, Kenemans P, Meijer CJ. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. J Clin Pathol 1995; 48:631 - 6; http://dx.doi.org/10.1136/jcp.48.7.631; PMID: 7560169
   PubMed Web of Science ®Google Scholar
• Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999; 8:775 - 82; PMID: 10498396
   PubMed Web of Science ®Google Scholar
• Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73:2432 - 43; http://dx.doi.org/10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; PMID: 7513252
   PubMed Web of Science ®Google Scholar
• Selhub J, Rosenberg IH. Folate transport in isolated brush border membrane vesicles from rat intestine. J Biol Chem 1981; 256:4489 - 93; PMID: 7217093
   PubMed Web of Science ®Google Scholar
• Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al. Identification of an intestinal heme transporter. Cell 2005; 122:789 - 801; http://dx.doi.org/10.1016/j.cell.2005.06.025; PMID: 16143108
   PubMed Web of Science ®Google Scholar
• Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127:917 - 28; http://dx.doi.org/10.1016/j.cell.2006.09.041; PMID: 17129779
   PubMed Web of Science ®Google Scholar
• Umapathy NS, Gnana-Prakasam JP, Martin PM, Mysona B, Dun Y, Smith SB, et al. Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types. Invest Ophthalmol Vis Sci 2007; 48:5299 - 305; http://dx.doi.org/10.1167/iovs.07-0288; PMID: 17962486
   PubMed Web of Science ®Google Scholar
• Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, et al. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther 2007; 322:469 - 76; http://dx.doi.org/10.1124/jpet.107.122606; PMID: 17475902
   PubMed Web of Science ®Google Scholar
• Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, et al. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am J Physiol Gastrointest Liver Physiol 2008; 294:G660 - 8; http://dx.doi.org/10.1152/ajpgi.00309.2007; PMID: 18174275
   PubMed Web of Science ®Google Scholar
• Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, et al. Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 2007; 293:C1669 - 78; http://dx.doi.org/10.1152/ajpcell.00202.2007; PMID: 17898134
   PubMed Web of Science ®Google Scholar
• Unal ES, Zhao R, Qiu A, Goldman ID. N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT). Biochim Biophys Acta 2008; 1778:1407 - 14; http://dx.doi.org/10.1016/j.bbamem.2008.03.009; PMID: 18405659
   PubMed Web of Science ®Google Scholar
• Zhao R, Unal ES, Shin DS, Goldman ID. Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. Biochemistry 2010; 49:2925 - 31; http://dx.doi.org/10.1021/bi9021439; PMID: 20225891
   PubMed Web of Science ®Google Scholar
• Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, et al. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 2012; 287:4982 - 95; http://dx.doi.org/10.1074/jbc.M111.306860; PMID: 22179615
   PubMed Web of Science ®Google Scholar
• Subramanian VS, Marchant JS, Said HM. Apical membrane targeting and trafficking of the human proton-coupled transporter in polarized epithelia. Am J Physiol Cell Physiol 2008; 294:C233 - 40; http://dx.doi.org/10.1152/ajpcell.00468.2007; PMID: 18003745
   PubMed Web of Science ®Google Scholar
• Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008; 74:854 - 62; http://dx.doi.org/10.1124/mol.108.045443; PMID: 18524888
   PubMed Web of Science ®Google Scholar
• Kugel Desmoulin S, Wang L, Polin L, White K, Kushner J, Stout M, et al. Functional Loss of the Reduced Folate Carrier Enhances the Antitumor Activities of Novel Antifolates with Selective Uptake by the Proton-coupled Folate Transporter. Mol Pharmacol 2012; In Press
   Web of Science ®Google Scholar
• Unal ES, Zhao R, Chang MH, Fiser A, Romero MF, Goldman ID. The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1. J Biol Chem 2009; 284:17846 - 57; http://dx.doi.org/10.1074/jbc.M109.008060; PMID: 19389703
   PubMed Web of Science ®Google Scholar
• Mahadeo K, Diop-Bove N, Shin D, Unal ES, Teo J, Zhao R, et al. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. Am J Physiol Cell Physiol 2010; 299:C1153 - 61; http://dx.doi.org/10.1152/ajpcell.00113.2010; PMID: 20686069
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Gregor JC, Chande N, Knauer MJ, Tirona RG, Kim RB. The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol 2010; 298:G248 - 54; http://dx.doi.org/10.1152/ajpgi.00224.2009; PMID: 19762432
   PubMed Web of Science ®Google Scholar
• Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem 2008; 104:1494 - 503; http://dx.doi.org/10.1111/j.1471-4159.2007.05095.x; PMID: 18086128
   PubMed Web of Science ®Google Scholar
• Diop-Bove NK, Wu J, Zhao R, Locker J, Goldman ID. Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther 2009; 8:2424 - 31; http://dx.doi.org/10.1158/1535-7163.MCT-08-0938; PMID: 19671745
   PubMed Web of Science ®Google Scholar
• Stark M, Gonen N, Assaraf YG. Functional elements in the minimal promoter of the human proton-coupled folate transporter. Biochem Biophys Res Commun 2009; 388:79 - 85; http://dx.doi.org/10.1016/j.bbrc.2009.07.116; PMID: 19643086
   PubMed Web of Science ®Google Scholar
• Gonen N, Bram EE, Assaraf YG. PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells. Biochem Biophys Res Commun 2008; 376:787 - 92; http://dx.doi.org/10.1016/j.bbrc.2008.09.074; PMID: 18817749
   PubMed Web of Science ®Google Scholar
• Gonen N, Assaraf YG. The obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1. J Biol Chem 2010; 285:33602 - 13; http://dx.doi.org/10.1074/jbc.M110.135640; PMID: 20724482
   PubMed Web of Science ®Google Scholar
• Scarpulla RC. Nucleus-encoded regulators of mitochondrial function: Integration of respiratory chain expression, nutrient sensing and metabolic stress. Biochim Biophys Acta 2011; 1819:1088 - 97; PMID: 22080153
   PubMed Web of Science ®Google Scholar
• Chang CM, Yu CC, Lu HT, Chou YF, Huang RFS. Folate deprivation promotes mitochondrial oxidative decay: DNA large deletions, cytochrome c oxidase dysfunction, membrane depolarization and superoxide overproduction in rat liver. Br J Nutr 2007; 97:855 - 63; http://dx.doi.org/10.1017/S0007114507666410; PMID: 17381984
   PubMed Web of Science ®Google Scholar
• Brayton KA, Chen Z, Zhou G, Nagy PL, Gavalas A, Trent JM, et al. Two genes for de novo purine nucleotide synthesis on human chromosome 4 are closely linked and divergently transcribed. J Biol Chem 1994; 269:5313 - 21; PMID: 8106516
   PubMed Web of Science ®Google Scholar
• Chen S, Nagy PL, Zalkin H. Role of NRF-1 in bidirectional transcription of the human GPAT-AIRC purine biosynthesis locus. Nucleic Acids Res 1997; 25:1809 - 16; http://dx.doi.org/10.1093/nar/25.9.1809; PMID: 9108165
   PubMed Web of Science ®Google Scholar
• Eloranta JJ, Zaïr ZM, Hiller C, Häusler S, Stieger B, Kullak-Ublick GA. Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol 2009; 76:1062 - 71; http://dx.doi.org/10.1124/mol.109.055392; PMID: 19666701
   PubMed Web of Science ®Google Scholar
• Zhao R, Min SH, Qiu A, Sakaris A, Goldberg GL, Sandoval C, et al. The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption. Blood 2007; 110:1147 - 52; http://dx.doi.org/10.1182/blood-2007-02-077099; PMID: 17446347
   PubMed Web of Science ®Google Scholar
• Min SH, Oh SY, Karp GI, Poncz M, Zhao R, Goldman ID. The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. J Pediatr 2008; 153:435 - 7; http://dx.doi.org/10.1016/j.jpeds.2008.04.009; PMID: 18718264
   PubMed Web of Science ®Google Scholar
• Lasry I, Berman B, Straussberg R, Sofer Y, Bessler H, Sharkia M, et al. A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function. Blood 2008; 112:2055 - 61; http://dx.doi.org/10.1182/blood-2008-04-150276; PMID: 18559978
   PubMed Web of Science ®Google Scholar
• Geller J, Kronn D, Jayabose S, Sandoval C. Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore) 2002; 81:51 - 68; http://dx.doi.org/10.1097/00005792-200201000-00004; PMID: 11807405
   PubMed Web of Science ®Google Scholar
• Shin DS, Min SH, Russell L, Zhao R, Fiser A, Goldman ID. Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood 2010; 116:5162 - 9; http://dx.doi.org/10.1182/blood-2010-06-291237; PMID: 20805364
   PubMed Web of Science ®Google Scholar
• Shin DS, Mahadeo K, Min SH, Diop-Bove N, Clayton P, Zhao R, et al. Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab 2011; 103:33 - 7; http://dx.doi.org/10.1016/j.ymgme.2011.01.008; PMID: 21333572
   PubMed Web of Science ®Google Scholar
• Atabay B, Turker M, Ozer EA, Mahadeo K, Diop-Bove N, Goldman ID. Mutation of the proton-coupled folate transporter gene (PCFT-SLC46A1) in Turkish siblings with hereditary folate malabsorption. Pediatr Hematol Oncol 2010; 27:614 - 9; http://dx.doi.org/10.3109/08880018.2010.481705; PMID: 20795774
   PubMed Web of Science ®Google Scholar
• Meyer E, Kurian MA, Pasha S, Trembath RC, Cole T, Maher ER. A novel PCFT gene mutation (p.Cys66LeufsX99) causing hereditary folate malabsorption. Mol Genet Metab 2010; 99:325 - 8; http://dx.doi.org/10.1016/j.ymgme.2009.11.004; PMID: 20005757
   PubMed Web of Science ®Google Scholar
• Unal ES, Zhao R, Goldman ID. Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. Am J Physiol Cell Physiol 2009; 297:C66 - 74; http://dx.doi.org/10.1152/ajpcell.00096.2009; PMID: 19403800
   PubMed Web of Science ®Google Scholar
• Borzutzky A, Crompton B, Bergmann AK, Giliani S, Baxi S, Martin M, et al. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clin Immunol 2009; 133:287 - 94; http://dx.doi.org/10.1016/j.clim.2009.08.006; PMID: 19740703
   PubMed Web of Science ®Google Scholar
• Zhao R, Shin DS, Diop-Bove N, Ovits CG, Goldman ID. Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of function. J Biol Chem 2011; 286:24150 - 8; http://dx.doi.org/10.1074/jbc.M111.236539; PMID: 21602279
   PubMed Web of Science ®Google Scholar
• Shin DS, Zhao R, Yap EH, Fiser A, Goldman IDA. A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. Am J Physiol Cell Physiol 2012; 302:C1405 - 12; http://dx.doi.org/10.1152/ajpcell.00435.2011; PMID: 22345511
   PubMedGoogle Scholar
• Veenhoff LM, Heuberger EH, Poolman B. Quaternary structure and function of transport proteins. Trends Biochem Sci 2002; 27:242 - 9; http://dx.doi.org/10.1016/S0968-0004(02)02077-7; PMID: 12076536
   PubMed Web of Science ®Google Scholar
• Hou Z, Kugel Desmoulin S, Etnyre E, Olive M, Hsiung B, Cherian C, et al. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem 2012; 287:4982 - 95; http://dx.doi.org/10.1074/jbc.M111.306860; PMID: 22179615
   PubMed Web of Science ®Google Scholar
• Duan P, Wu J, You G. Mutational analysis of the role of GXXXG motif in the function of human organic anion transporter 1 (hOAT1). Int J Biochem Mol Biol 2011; 2:1 - 7; PMID: 21340049
   PubMedGoogle Scholar
• Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, et al. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 2010; 49:2235 - 45; http://dx.doi.org/10.1021/bi902085q; PMID: 20088606
   PubMed Web of Science ®Google Scholar
• Zhao R, Shin DS, Fiser A, Goldman ID. Identification of a functionally critical GXXG motif and its relationship to the folate binding site of the proton-coupled folate transporter (PCFT-SLC46A1). Am J Physiol Cell Physiol 2012; In Press http://dx.doi.org/10.1152/ajpcell.00123.2012; PMID: 22785121
   PubMed Web of Science ®Google Scholar
• Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003; 301:610 - 5; http://dx.doi.org/10.1126/science.1088196; PMID: 12893935
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6:404 - 17; http://dx.doi.org/10.1158/1535-7163.MCT-06-0343; PMID: 17308042
   PubMed Web of Science ®Google Scholar
• Chládek J, Martínková J, Simková M, Vanecková J, Koudelková V, Nozicková M. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53:437 - 44; http://dx.doi.org/10.1007/s002280050404; PMID: 9551702
   PubMed Web of Science ®Google Scholar
• Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al, The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992; 326:1043 - 9; http://dx.doi.org/10.1056/NEJM199204163261602; PMID: 1549149
   PubMed Web of Science ®Google Scholar
• Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol 2009; 5:1447 - 54; http://dx.doi.org/10.1517/17425250903307455; PMID: 19863453
   PubMed Web of Science ®Google Scholar
• Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 2003; 52:Suppl 1 S80 - 9; http://dx.doi.org/10.1007/s00280-003-0625-9; PMID: 12819937
   PubMed Web of Science ®Google Scholar
• Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28:77 - 102; http://dx.doi.org/10.1016/0163-7258(85)90083-X; PMID: 2414788
   PubMed Web of Science ®Google Scholar
• Hughes LR, Stephens TC, Boyle FT, Jackman AL. Raltitrexed (Tomudex), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor. In: Jackman AL, ed. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc., 1999:147-65.
   Google Scholar
• Mendelsohn LG, Worzalla JF, Walling JM. Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887. In: Jackman AL, ed. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc., 1999:261-80.
   Google Scholar
• Shih C, Thornton DE. Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514). In: Jackman AL, ed. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, Inc., 1999:183-201.
   Google Scholar
• Trent DF, Seither RL, Goldman ID. Rate and extent of interconversion of tetrahydrofolate cofactors to dihydrofolate after cessation of dihydrofolate reductase activity in stationary versus log phase L1210 leukemia cells. J Biol Chem 1991; 266:5445 - 9; PMID: 1825999
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Fine RL, Drake JC, Chabner BA. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem 1986; 261:6478 - 85; PMID: 3700401
   PubMed Web of Science ®Google Scholar
• Matherly LH, Seither RL, Goldman ID. Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates. Pharmacol Ther 1987; 35:27 - 56; http://dx.doi.org/10.1016/0163-7258(87)90104-5; PMID: 2447596
   PubMed Web of Science ®Google Scholar
• Trent DF, Seither RL, Goldman ID. Compartmentation of intracellular folates. Failure to interconvert tetrahydrofolate cofactors to dihydrofolate in mitochondria of L1210 leukemia cells treated with trimetrexate. Biochem Pharmacol 1991; 42:1015 - 9; http://dx.doi.org/10.1016/0006-2952(91)90283-B; PMID: 1831361
   PubMed Web of Science ®Google Scholar
• Matherly LH, Muench SP. Evidence for a localized conversion of endogenous tetrahydrofolate cofactors to dihydrofolate as an important element in antifolate action in murine leukemia cells. Biochem Pharmacol 1990; 39:2005 - 14; http://dx.doi.org/10.1016/0006-2952(90)90622-R; PMID: 2141258
   PubMed Web of Science ®Google Scholar
• Tibbetts AS, Appling DR. Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr 2010; 30:57 - 81; http://dx.doi.org/10.1146/annurev.nutr.012809.104810; PMID: 20645850
   PubMed Web of Science ®Google Scholar
• Matherly LH, Voss MK, Anderson LA, Fry DW, Goldman ID. Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro. Cancer Res 1985; 45:1073 - 8; PMID: 2578870
   PubMed Web of Science ®Google Scholar
• Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, et al. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther 2012; 342:696 - 708; http://dx.doi.org/10.1124/jpet.112.195479; PMID: 22653877
   PubMed Web of Science ®Google Scholar
• Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, et al. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2008; 62:65 - 75; http://dx.doi.org/10.1007/s00280-007-0576-7; PMID: 17768625
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984; 12:26 - 30; PMID: 6690070
   PubMed Web of Science ®Google Scholar
• Schmid FA, Sirotnak FM, Otter GM, DeGraw JI. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 1985; 69:551 - 3; PMID: 4005878
   PubMedGoogle Scholar
• Sirotnak FM, Otter GM, Schmid FA. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors. Cancer Res 1993; 53:587 - 91; PMID: 8425192
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998; 42:313 - 8; http://dx.doi.org/10.1007/s002800050823; PMID: 9744777
   PubMed Web of Science ®Google Scholar
• Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, et al. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003; 9:2072 - 8; PMID: 12796370
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357 - 64; http://dx.doi.org/10.1200/JCO.2008.20.8470; PMID: 19652067
   PubMed Web of Science ®Google Scholar
• Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995; 6:871 - 81; PMID: 8624289
   PubMed Web of Science ®Google Scholar
• Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51:5579 - 86; PMID: 1913676
   PubMed Web of Science ®Google Scholar
• Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther 2011; 11:1481 - 90; http://dx.doi.org/10.1586/era.11.136; PMID: 21999120
   PubMed Web of Science ®Google Scholar
• Theti DS, Bavetsias V, Skelton LA, Titley J, Gibbs D, Jansen G, et al. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 2003; 63:3612 - 8; PMID: 12839949
   PubMed Web of Science ®Google Scholar
• Jackson RC, Harkrader RJ. The contributions of de-novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. In: Tattersall MHN, Fox RM, eds. Nucleosides and Cancer Treatment. Sydney: Academic Press, 1981:18-31.
   Google Scholar
• Howell SB, Mansfield SJ, Taetle R. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res 1981; 41:945 - 50; PMID: 6257387
   PubMed Web of Science ®Google Scholar
• Moran RG, Baldwin SW, Taylor EC, Shih C. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem 1989; 264:21047 - 51; PMID: 2592365
   PubMed Web of Science ®Google Scholar
• Taylor EC, Harrington PJ, Fletcher SR, Beardsley GP, Moran RG. Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. J Med Chem 1985; 28:914 - 21; http://dx.doi.org/10.1021/jm00145a012; PMID: 4009615
   PubMed Web of Science ®Google Scholar
• Jansen G. Receptor- and carrier- mediated transport system for folates and antifolates. In: Jackman AL, ed. Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press Inc., 1999:293-321.
   Google Scholar
• Beardsley GP, Moroson BA, Taylor EC, Moran RG. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 1989; 264:328 - 33; PMID: 2909524
   PubMed Web of Science ®Google Scholar
• Matherly LH, Angeles SM, McGuire JJ. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Biochem Pharmacol 1993; 46:2185 - 95; http://dx.doi.org/10.1016/0006-2952(93)90608-Y; PMID: 7506026
   PubMed Web of Science ®Google Scholar
• Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, et al. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 1993; 85:1154 - 9; http://dx.doi.org/10.1093/jnci/85.14.1154; PMID: 8320744
   PubMed Web of Science ®Google Scholar
• Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, et al. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 2000; 45:103 - 10; http://dx.doi.org/10.1007/s002800050017; PMID: 10663624
   PubMed Web of Science ®Google Scholar
• Boritzki TJ, Barlett CA, Zhang C, Howland EF. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996; 14:295 - 303; http://dx.doi.org/10.1007/BF00194533; PMID: 8958185
   PubMed Web of Science ®Google Scholar
• Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, et al. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 2001; 84:308 - 12; http://dx.doi.org/10.1054/bjoc.2000.1601; PMID: 11161393
   PubMed Web of Science ®Google Scholar
• Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, et al. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemother Pharmacol 2001; 47:525 - 31; http://dx.doi.org/10.1007/s002800000272; PMID: 11459206
   PubMed Web of Science ®Google Scholar
• Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992; 35:4450 - 4; http://dx.doi.org/10.1021/jm00101a023; PMID: 1447744
   PubMed Web of Science ®Google Scholar
• Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116 - 23; PMID: 9067281
   PubMed Web of Science ®Google Scholar
• Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001; 61:857 - 65; http://dx.doi.org/10.1016/S0006-2952(01)00532-9; PMID: 11274972
   PubMed Web of Science ®Google Scholar
• Zhao R, Chattopadhyay S, Hanscom M, Goldman ID. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res 2004; 10:8735 - 42; http://dx.doi.org/10.1158/1078-0432.CCR-04-0932; PMID: 15623659
   PubMed Web of Science ®Google Scholar
• Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004; 10:718 - 27; http://dx.doi.org/10.1158/1078-0432.CCR-1066-03; PMID: 14760095
   PubMed Web of Science ®Google Scholar
• Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res 2004; 64:3313 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-03-3953; PMID: 15126375
   PubMed Web of Science ®Google Scholar
• Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009; 69:5467 - 74; http://dx.doi.org/10.1158/0008-5472.CAN-08-4979; PMID: 19549896
   PubMed Web of Science ®Google Scholar
• Rothbart SB, Racanelli AC, Moran RG. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 2010; 70:10299 - 309; http://dx.doi.org/10.1158/0008-5472.CAN-10-1873; PMID: 21159649
   PubMed Web of Science ®Google Scholar
• Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 2011; 71:4955 - 67; http://dx.doi.org/10.1158/0008-5472.CAN-11-0898; PMID: 21622715
   PubMed Web of Science ®Google Scholar
• Cohen MH, Cortazar P, Justice R, Pazdur R. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010; 15:1352 - 8; http://dx.doi.org/10.1634/theoncologist.2010-0224; PMID: 21148615
   PubMed Web of Science ®Google Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27:441 - 64; http://dx.doi.org/10.1146/annurev-cellbio-092910-154237; PMID: 21985671
   PubMed Web of Science ®Google Scholar
• Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993; 265:C1015 - 29; PMID: 8238296
   PubMed Web of Science ®Google Scholar
• McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 2000; 278:C676 - 88; PMID: 10751317
   PubMed Web of Science ®Google Scholar
• Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010; 2010:427694; http://dx.doi.org/10.1155/2010/427694; PMID: 20454640
   PubMed Web of Science ®Google Scholar
• Chiche J, Le Fur Y, Vilmen C, Frassineti F, Daniel L, Halestrap AP, et al. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH. Int J Cancer 2012; 130:1511 - 20; http://dx.doi.org/10.1002/ijc.26125; PMID: 21484790
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009; 69:358 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-08-2470; PMID: 19118021
   PubMed Web of Science ®Google Scholar
• Alper SL. Molecular physiology and genetics of Na+-independent SLC4 anion exchangers. J Exp Biol 2009; 212:1672 - 83; http://dx.doi.org/10.1242/jeb.029454; PMID: 19448077
   PubMed Web of Science ®Google Scholar
• Boron WF, Chen L, Parker MD. Modular structure of sodium-coupled bicarbonate transporters. J Exp Biol 2009; 212:1697 - 706; http://dx.doi.org/10.1242/jeb.028563; PMID: 19448079
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16:430 - 50; http://dx.doi.org/10.1002/jmri.10181; PMID: 12353258
   PubMed Web of Science ®Google Scholar
• Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008; 453:940 - 3; http://dx.doi.org/10.1038/nature07017; PMID: 18509335
   PubMed Web of Science ®Google Scholar
• Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011; 11:671 - 7; http://dx.doi.org/10.1038/nrc3110; PMID: 21833026
   PubMed Web of Science ®Google Scholar
• Anderson CM, Thwaites DT. Hijacking solute carriers for proton-coupled drug transport. Physiology (Bethesda) 2010; 25:364 - 77; http://dx.doi.org/10.1152/physiol.00027.2010; PMID: 21186281
   PubMed Web of Science ®Google Scholar
• Anderson CM, Jevons M, Thangaraju M, Edwards N, Conlon NJ, Woods S, et al. Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther 2010; 332:220 - 8; http://dx.doi.org/10.1124/jpet.109.159822; PMID: 19789362
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 2000; 88:274 - 80; http://dx.doi.org/10.1002/1097-0215(20001015)88:2<274::AID-IJC20>3.0.CO;2-5; PMID: 11004680
   PubMed Web of Science ®Google Scholar
• Sun Y, Sun J, Shi S, Jing Y, Yin S, Chen Y, et al. Synthesis, transport and pharmacokinetics of 5′-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. Mol Pharm 2009; 6:315 - 25; http://dx.doi.org/10.1021/mp800200a; PMID: 19115956
   PubMed Web of Science ®Google Scholar
• Anderson CM, Grenade DS, Boll M, Foltz M, Wake KA, Kennedy DJ, et al. H+/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat. Gastroenterology 2004; 127:1410 - 22; http://dx.doi.org/10.1053/j.gastro.2004.08.017; PMID: 15521011
   PubMed Web of Science ®Google Scholar
• Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006; 318:521 - 9; http://dx.doi.org/10.1124/jpet.106.104364; PMID: 16702441
   PubMed Web of Science ®Google Scholar
• Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995; 270:17468 - 75; http://dx.doi.org/10.1074/jbc.270.29.17468; PMID: 7615551
   PubMed Web of Science ®Google Scholar
• Shih C, Barnett CJ, Grindey GB, Pearce HL, Engelhardt JA, Todd GC, et al. Structural Features That Determine the Biological Activity of Pyrrolo[2,3-d]pyrimidine Based Antifolates. The 10th International Symposium, Chemistry and Biology of Pteridines and Folates. Orange Beach, AL, 1993:Abstr F15.
   Google Scholar
• Gangjee A, Zeng Y, McGuire JJ, Mehraein F, Kisliuk RL. Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates. J Med Chem 2004; 47:6893 - 901; http://dx.doi.org/10.1021/jm040123k; PMID: 15615538
   PubMed Web of Science ®Google Scholar
• Gangjee A, Zeng Y, McGuire JJ, Kisliuk RL. Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates. J Med Chem 2005; 48:5329 - 36; http://dx.doi.org/10.1021/jm058213s; PMID: 16078850
   PubMed Web of Science ®Google Scholar
• Gates SB, Worzalla JF, Shih C, Grindey GB, Mendelsohn LG. Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts. Biochem Pharmacol 1996; 52:1477 - 9; http://dx.doi.org/10.1016/S0006-2952(96)00554-0; PMID: 8937460
   PubMed Web of Science ®Google Scholar
• Ifergan I, Jansen G, Assaraf YG. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Mol Pharmacol 2005; 67:1349 - 59; http://dx.doi.org/10.1124/mol.104.008250; PMID: 15657365
   PubMed Web of Science ®Google Scholar
• Bronder JL, Moran RG. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res 2002; 62:5236 - 41; PMID: 12234990
   PubMed Web of Science ®Google Scholar
• Bronder JL, Moran RG. A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 2003; 278:48861 - 71; http://dx.doi.org/10.1074/jbc.M304844200; PMID: 14517211
   PubMed Web of Science ®Google Scholar
• Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003; 9:2108 - 13; PMID: 12796375
   PubMed Web of Science ®Google Scholar
• Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996; 56:5653 - 8; PMID: 8971171
   PubMed Web of Science ®Google Scholar
• An S, Kumar R, Sheets ED, Benkovic SJ. Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science 2008; 320:103 - 6; http://dx.doi.org/10.1126/science.1152241; PMID: 18388293
   PubMed Web of Science ®Google Scholar